Xu N - Search Results

1

Prophylaxis of neutropenia with mecapegfilgrastim in patients with non-myeloid malignancies: a real-world study.

Ma J, Huang H, Fu P, Xu N, Mao C, Cheng G, Yan H, Li Y, Shi Y, Wang Y, Yao Y, Chen L, Chen Y, Zhang N, Zhang G, Ren Z, Li Z, Song L, Xu R, Qin S. Ma J, et al. Among authors: xu n, xu r. Ann Transl Med. 2021 May;9(10):893. doi: 10.21037/atm-21-2449. Ann Transl Med. 2021. PMID: 34164527 Free PMC article.

2

Characteristic CYP2A6 genetic polymorphisms detected by TA cloning-based sequencing in Chinese digestive system cancer patients with S-1 based chemotherapy.

Fang WJ, Mou HB, Jin DZ, Zheng YL, Zhao P, Mao CY, Peng L, Huang MZ, Xu N. Fang WJ, et al. Among authors: xu n. Oncol Rep. 2012 May;27(5):1606-10. doi: 10.3892/or.2012.1678. Epub 2012 Feb 7. Oncol Rep. 2012. PMID: 22322240

3

Complete remission of platinum-refractory primary Fallopian tube carcinoma with third-line gemcitabine plus cisplatin: A case report and review of the literature.

Xu Q, Xu N, Fang W, Zhao P, Mao C, Zheng Y, Mou H. Xu Q, et al. Among authors: xu n. Oncol Lett. 2013 May;5(5):1601-1604. doi: 10.3892/ol.2013.1232. Epub 2013 Mar 6. Oncol Lett. 2013. PMID: 23759738 Free PMC article.

4

Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study.

Zheng Y, Fang W, Mao C, Qian J, Zhao P, Zhang X, Jiang H, Zheng Y, Xu N. Zheng Y, et al. Among authors: xu n. Cancer Chemother Pharmacol. 2014 Sep;74(3):503-9. doi: 10.1007/s00280-014-2537-2. Epub 2014 Jul 20. Cancer Chemother Pharmacol. 2014. PMID: 25038612 Clinical Trial.

5

A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer.

Jiang H, Qian J, Zhao P, Zhang X, Zheng Y, Mao C, Zheng Y, Chen L, Wang Y, Mou H, Fang W, Teng L, Xu N. Jiang H, et al. Among authors: xu n. Cancer Chemother Pharmacol. 2015 Jul;76(1):197-203. doi: 10.1007/s00280-015-2782-z. Epub 2015 May 27. Cancer Chemother Pharmacol. 2015. PMID: 26013324 Clinical Trial.

6

Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer.

Wang ZQ, Zhang DS, Xu N, Luo DY, Deng YH, Wang FH, Luo HY, Qiu MZ, Li YH, Xu RH. Wang ZQ, et al. Among authors: xu n, xu rh. Chin J Cancer. 2016 Jan 6;35:8. doi: 10.1186/s40880-015-0061-3. Chin J Cancer. 2016. PMID: 26739998 Free PMC article. Clinical Trial.

7

Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.

Gong J, Liu T, Fan Q, Bai L, Bi F, Qin S, Wang J, Xu N, Cheng Y, Bai Y, Liu W, Wang L, Shen L. Gong J, et al. Among authors: xu n. BMC Cancer. 2016 Feb 8;16:68. doi: 10.1186/s12885-016-2092-9. BMC Cancer. 2016. PMID: 26857702 Free PMC article. Clinical Trial.

8

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.

Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, Wang Z, Wang Q, Ouyang X, Yang Y, Ba Y, Liang J, Lin X, Luo D, Zheng R, Wang X, Sun G, Wang L, Zheng L, Guo H, Wu J, Xu N, Yang J, Zhang H, Cheng Y, Wang N, Chen L, Fan Z, Sun P, Yu H. Li J, et al. Among authors: xu n, xu r, xu j. J Clin Oncol. 2016 May 1;34(13):1448-54. doi: 10.1200/JCO.2015.63.5995. Epub 2016 Feb 16. J Clin Oncol. 2016. PMID: 26884585 Clinical Trial.

9

Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study.

Liu X, Qin S, Wang Z, Xu J, Xiong J, Bai Y, Wang Z, Yang Y, Sun G, Wang L, Zheng L, Xu N, Cheng Y, Guo W, Yu H, Liu T, Lagiou P, Li J. Liu X, et al. Among authors: xu n, xu j. J Hematol Oncol. 2017 Sep 5;10(1):153. doi: 10.1186/s13045-017-0521-0. J Hematol Oncol. 2017. PMID: 28870253 Free PMC article.

10

Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.

Bang YJ, Xu RH, Chin K, Lee KW, Park SH, Rha SY, Shen L, Qin S, Xu N, Im SA, Locker G, Rowe P, Shi X, Hodgson D, Liu YZ, Boku N. Bang YJ, et al. Among authors: xu n, xu rh. Lancet Oncol. 2017 Dec;18(12):1637-1651. doi: 10.1016/S1470-2045(17)30682-4. Epub 2017 Nov 2. Lancet Oncol. 2017. PMID: 29103871 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,025 results

Search Page

Filters